<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02205099</url>
  </required_header>
  <id_info>
    <org_study_id>SKL15508C003</org_study_id>
    <nct_id>NCT02205099</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia</brief_title>
  <official_title>A Single-center, Randomized, Double-blind, Flexible-dosage, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Life Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Life Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-site, randomized, double-blind, placebo-controlled, multiple dose, flexible
      dosage range, PK and PD study of SKL15508 as monotherapy in subjects with stable
      schizophrenia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and percent of subjects experiencing an adverse event.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in event-related potentials (ERP) following multiple oral doses of SKL15508.</measure>
    <time_frame>During the course of 10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in clinical laboratory assessments.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in vital signs.</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SKL15508 High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKL15508 High Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKL15508 Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKL15508 Medium Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SKL15508 Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SKL15508 Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKL15508</intervention_name>
    <arm_group_label>SKL15508 High Dose</arm_group_label>
    <arm_group_label>SKL15508 Medium Dose</arm_group_label>
    <arm_group_label>SKL15508 Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The subject or, when applicable, the subject's legally acceptable representative signs
             and dates a written, informed consent form and any required privacy authorization
             prior to the initiation of any study procedures.

          2. Participants who are nonsterile and sexually active agree to use a double-barrier
             method of contraception (must be used regardless of any other contraception in use)
             from the time of providing informed consent throughout the duration of the study and
             for 12 weeks after the last dose of study drug. Nonsterile males must be advised not
             to donate sperm and women should not donate ova throughout the duration of the study
             and for 12 weeks after the last dose of study drug.

          3. Must be male or non-pregnant, non-lactating female subjects, 18 to 60 years of age,
             inclusive

          4. Has a body mass index (BMI) between 18.0 and 38.0 kg/m2, inclusive

          5. Has a clinical diagnosis of schizophrenia and, in the opinion of the Investigator, is
             able to safely be off his or her prescribed antipsychotic medications while
             participating in the study and has a very high likelihood of not deteriorating over a
             3-week timeframe when off standard of care as outpatients during the Screening Period

          6. Has been receiving a stable dose of antipsychotic medication for at least 1 month
             before Screening

          7. Has not had an acute exacerbation of psychosis or hospitalization for the treatment of
             schizophrenia for at least 3 months before Screening

          8. By history, has not had a marked change in smoking or tobacco/nicotine use from 30
             days before Screening.

          9. Must reside in a stable residence for at least 8 weeks before the Screening Visit

        Exclusion Criteria:

          1. At risk of suicide (e.g., per Columbia Suicide Severity Rating Scale [C-SSRS]) or have
             made a suicide attempt in the 6 months before Screening

          2. Has a known sensitivity to sulfur-containing drugs or sulfates in food

          3. Taking any medication known to influence coagulation, such as acetylsalicylic acid
             (aspirin), and including prescription, herbal remedies, vitamin supplements and
             over-the-counter products

          4. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary,
             hepatic, renal, metabolic, gastrointestinal or endocrine disease or other abnormality
             (other than the disease being studied), which may impact the ability of the subject to
             participate or potentially confound the study results

          5. Has a positive urine drug result for drugs of abuse (i.e., illicit, illegal or without
             valid prescription or medical need) at Screening or Admission

          6. Has donated or lost 450 mL or more of his or her blood volume (including
             plasmapheresis), or had a transfusion of any blood product within 45 days before Day 1

          7. Has an abnormal (clinically significant) electrocardiogram (ECG) at Screening or unit
             admission day

          8. Has a blood pressure and pulse rate outside the protocol defined ranges

          9. Has a QT interval or PR outside of the protocol defined ranges

         10. Has abnormal laboratory values that suggest a clinically significant underlying
             disease

         11. Has a history of a primary DSM-IV axis I diagnosis other than schizophrenia

         12. Has a medical condition other than schizophrenia (e.g., dementia, antisocial
             personality, borderline personality disorders) that can cause cognitive impairment or
             interfere with the performance or completion of study-defined procedures

         13. Has been taking medication for a medical condition for less than 2 months even if at a
             stable dose or regimen

         14. Currently taking lithium or any psychotropic medication that cannot be discontinued
             for safety reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Glendale Adventist Medical Center</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2014</study_first_submitted>
  <study_first_submitted_qc>July 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2014</study_first_posted>
  <disposition_first_submitted>October 12, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>October 12, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 13, 2016</disposition_first_posted>
  <last_update_submitted>October 12, 2016</last_update_submitted>
  <last_update_submitted_qc>October 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

